Cumberland Pharmaceuticals (CPIX) Reports Q2 EPS of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results
August 2, 2016 4:05 PM EDTNASHVILLE, Tenn., Aug. 2, 2016 /PRNewswire/ --Â Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2016 financial results with Net Revenues of $7.4 million and Adjusted Earnings of $0.7 million or $0.04 per share.
As of June 30, 2016, the Company had approximately $88 million in Total Assets including $50 million in cash and marketable securities. Total Liabilities were approximately $14 million and Total Shareholder's Equity was just over $74 million. Cumberland also had approximately $43 million in tax net... More
